Alanyl Glutamine

Alanyl Glutamine

SCHEMBL8427100

C[C@H](N)C(=O)N[C@H](CCC(N)=O)C(=O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 1/20 0.59
KMT2A Q03164 2/20 0.47
ALOX15 P16050 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
DPP4 P27487 1/20 0.46
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46
FOLH1 Q04609 4/20 0.46
CA2 P00918 4/20 0.44
CA1 P00915 3/20 0.44
NAALAD2 Q9Y3Q0 2/20 0.44
RIMKLA Q8IXN7 1/20 0.44
ECE1 P42892 2/20 0.44
BMP1 P13497 1/20 0.43
ACE P12821 1/20 0.41
PRSS1 P07477 2/20 0.40
TMPRSS15 P98073 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alanyl Glutamine SCHEMBL133886 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL31140886 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL28215332 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL1009705 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL4274839 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL8813935 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL133887 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL29804717 1.00 NOD1 (0.59) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL21518502 0.98 NOD1 (0.58) NOD1KMT2AALOX15BLMPMP22
Alanyl Glutamine SCHEMBL21518470 0.98 NOD1 (0.58) NOD1KMT2AALOX15BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122031666-A Application of recombinant DL-endopeptidase and metabolite thereof in preparation of medicine for preventing premature infant late-onset septicemia 南方医科大学珠江医院 2026-05-15 CN claimed
CN-110702819-B Method for separating and measuring polypeptide chiral isomers containing multiple chiral centers by using high performance liquid chromatography 浙江美测医药科技有限公司 2022-09-06 CN claimed
EP-0635026-B1 NOVEL LIPOPHILIC OLIGOPEPTIDES WITH IMMUNOMODULATING ACTIVITY IAF BIOCHEM INT (CA) 1999-11-10 EP claimed
WO-1997005889-A1 NON-SPECIFIC VACCINATION BY D-AMINO-ACID CONTAINING COMPOUNDS SLESAREV VLADIMIR I (US) 1997-02-20 WO claimed
CN-122031666-A Application of recombinant DL-endopeptidase and metabolite thereof in preparation of medicine for preventing premature infant late-onset septicemia 南方医科大学珠江医院 2026-05-15 CN disclosed
EP-4739700-A1 RESPIRATORY SYNCYTIAL VIRUS MUTANTS, FUSION PEPTIDES, PARTICLES, NUCLEIC ACIDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE Emory University (US) 2026-05-13 EP disclosed
WO-2025089217-A1 COMPOUND FOR USE AS SUBSTRATE FOR EVALUATING ACTIVITY OF γ-D-GLUTAMYL-L-LYSYL ENDOPEPTIDASE 株式会社ヤクルト本社 2025-05-01 WO disclosed
WO-2025075887-A2 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING HEPATITIS C VIRAL INFECTIONS EMORY UNIVERSITY (US) 2025-04-10 WO disclosed
WO-2025014822-A1 RESPIRATORY SYNCYTIAL VIRUS MUTANTS, FUSION PEPTIDES, PARTICLES, NUCLEIC ACIDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE EMORY UNIVERSITY (US) 2025-01-16 WO disclosed
US-20240238361-A1 METHODS OF TREATING FIBROSIS AND HYPOXIA-ASSOCIATED DAMAGE TO PERIPHERAL NERVES Temple Therapeutics BV (NL) 2024-07-18 US disclosed
WO-2024073697-A1 RSV VACCINES WITH TRUNCATED G-PROTEIN MUCIN DOMAINS EMORY UNIVERSITY (US) 2024-04-04 WO disclosed
EP-4333828-A1 METHODS OF TREATING FIBROSIS AND HYPOXIA-ASSOCIATED DAMAGE TO PERIPHERAL NERVES Temple Therapeutics BV (NL) 2024-03-13 EP disclosed
US-20220127590-A1 STREPTOCOCCUS BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIA UNIV ROCKEFELLER (US) 2022-04-28 US disclosed
CN-114381470-A Artificial nucleic acid molecules 库瑞瓦格股份公司 2022-04-22 CN disclosed
CN-110702819-A Method for separating and measuring polypeptide chiral isomers containing multiple chiral centers by using high performance liquid chromatography 浙江美测医药科技有限公司 2020-01-17 CN disclosed
CN-110392577-A RNA vaccines and immune checkpoint inhibitors for combination anti-cancer therapy 库尔维科公司 2019-10-29 CN disclosed
CN-110352071-A Lipidic nanoparticles mRNA vaccine 库瑞瓦格股份公司 2019-10-18 CN disclosed
CN-103360462-B Refining method of alanyl-glutamine crude drug SHANDONG QIDU PHARMACEUTICAL 2015-06-24 CN disclosed
WO-1990006322-A1 PEPTIDOGLUCAN DIMERS, PROCESS FOR PRODUCING THEM AND THEIR USE AS IMMUNOMODULATORS HELOPHARM W. PETRIK GMBH & CO., KG (DE) 1990-06-14 WO disclosed
EP-0006068-B1 COMPOUNDS OF THE MURAMYL-PEPTIDE TYPE AND MEDICINES CONTAINING THEM ANVAR Agence Nationale de Valorisation de la Recherche (FR) 1983-09-21 EP disclosed